Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ817MR)

This product GTTS-WQ817MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ817MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8898MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ15085MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ST2146
GTTS-WQ6221MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ13168MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04518600
GTTS-WQ7954MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ1323MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ799MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Ab-2
GTTS-WQ12998MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PEG-G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW